BCL9L Antikörper (N-Term)

Produktnummer ABIN1881110

Produktdetails anti-BCL9L Antikörper

Target: BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))

Bindungsspezifität: AA 147-176, N-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser BCL9L Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This BCL9L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 147-176 amino acids from the N-terminal region of human BCL9L.

Klon: RB41624

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Referenzen für anti-BCL9L Antikörper (ABIN1881110)

Miller, Rutherford, Johnson, Fiedler, Bienz: "Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor." in: Journal of molecular biology, Vol. 401, Issue 5, pp. 969-84, (2010) (PubMed).

Fritzmann, Morkel, Besser, Budczies, Kosel, Brembeck, Stein, Fichtner, Schlag, Birchmeier: "A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential." in: Gastroenterology, Vol. 137, Issue 1, pp. 165-75, (2009) (PubMed).

Sampietro, Dahlberg, Cho, Hinds, Kimelman, Xu: "Crystal structure of a beta-catenin/BCL9/Tcf4 complex." in: Molecular cell, Vol. 24, Issue 2, pp. 293-300, (2006) (PubMed).

Brembeck, Schwarz-Romond, Bakkers, Wilhelm, Hammerschmidt, Birchmeier: "Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions." in: Genes & development, Vol. 18, Issue 18, pp. 2225-30, (2004) (PubMed).

Details zu BCL9L

Target: BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))

Andere Bezeichnung: BCL9L (BCL9L Produkte)

Synonyme: BCL9-2 antikoerper, DLNB11 antikoerper, B9L antikoerper, BC003321 antikoerper, bcl9-2 antikoerper, BCL9L antikoerper, B-cell CLL/lymphoma 9 like antikoerper, B cell CLL/lymphoma 9-like antikoerper, B-cell CLL/lymphoma 9-like antikoerper, BCL9L antikoerper, Bcl9l antikoerper, bcl9l antikoerper

Hintergrund: Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).

Molekulargewicht: 157129

NCBI Accession: NP_872363

UniProt: Q86UU0

Pathways: Stem Cell Maintenance